AGREEMENT ---------Stock Option Agreement • October 13th, 2000 • Sangui Biotech International Inc • Non-operating establishments • California
AMENDMENT TO THE SERVICE AGREEMENT Between 1) Axel Kleinkorres Promotionsagentur, proprietor Axel Kleinkorres, registered offices at M nsterstr. 306 D-40470 D sseldorf - referred to hereinafter as Promotion agency" - and 2) Sangui BioTech...Service Agreement • October 13th, 2000 • Sangui Biotech International Inc • Non-operating establishments
EQUITY PURCHASE AGREEMENT BY AND BETWEEN SANGUI BIOTECH INTERNATIONAL, INC. AND TARPON BAY PARTNERS LLC Dated May 11, 2015Equity Purchase Agreement • June 25th, 2015 • Sangui Biotech International Inc • Pharmaceutical preparations • New York
THIS EQUITY PURCHASE AGREEMENT entered into as of the 11th day of May, 2015 (this "AGREEMENT"), by and between TARPON BAY PARTNERS LLC, a Florida limited liability company ("INVESTOR"), and SANGUI BIOTECH INTERNATIONAL, INC., a Colorado corporation (the "COMPANY").
andFee Agreement • October 13th, 2000 • Sangui Biotech International Inc • Non-operating establishments
SERVICE AGREEMENT between 1) Axel Kleinkorres Promotionsagentur, proprietor Axel Kleinkorres, registered offices at Munsterstr. 306 D-40470 Dusseldorf - referred to hereinafter as "Promotion agency" - and 2) Sangui Bio Tech International, Inc.,...Service Agreement • October 13th, 2000 • Sangui Biotech International Inc • Non-operating establishments • California
ARTICLE 1.Consulting Agreement • March 1st, 2005 • Sangui Biotech International Inc • Pharmaceutical preparations
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 25th, 2015 • Sangui Biotech International Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement ("Agreement"), dated May 11, 2015, is made by and between SANGUI BIOTECH INTERNATIONAL, INC., a Colorado corporation ("Company"), and TARPON BAY PARTNERS LLC, a Florida limited liability company (the "Investor").
SERVICE CONTRACT Between GlukoMediTech AG Forschungs- und Entwicklungszentrum (FEZ) Alfred-Herrhausen-Str. 44 D-58455 Witten an der Ruhr represented by the Supervisory Board, the latter represented by its President, Axel J. Kutscher, Frankensteiner...Service Contract • October 13th, 2000 • Sangui Biotech International Inc • Non-operating establishments
LEASE CONTRACT FOR BUSINESS ROOMS Contract No.: 69 Copy for Landlord/Tenant The lease parties are referred to as Landlord and Tenant even if they are composed of several, maybe legal persons. All persons mentioned in the contract - in case of firms...Lease Contract • October 13th, 2000 • Sangui Biotech International Inc • Non-operating establishments
THE COMPANIES ACT, CAP. 50 REPUBLIC OF SINGAPORE PRIVATE COMPANY LIMITED BY SHARES _____________________________________________ MEMORANDUM AND ARTICLES OF ASSOCIATION OF SANGUI BIOTECH SINGAPORE PTE. LTD. Incorporated on the 25th day of May 1999...Sangui Biotech International Inc • November 20th, 2000 • Non-operating establishments
ADDITIONAL AGREEMENT TO LEASE CONTRACT NO. 69/2000 between Research and Development Centre, FEZ Witten GmbH, Alfred-Herrhausen-Str. 44, 58455 Witten and GlukoMediTech AG Witten, Alfred-Herrhausen-Str. 44, 58455 Witten concerning the lease of...Additional Agreement • October 13th, 2000 • Sangui Biotech International Inc • Non-operating establishments
STOCK EXCHANGE AGREEMENT Agreement dated as of March 31, 2000 between Sangui Biotech International, Inc., a Colorado corporation ("SGBI"), on the one hand, and MRC Legal Services LLC ("MRC" or the "Shareholder"). 1. THE ACQUISITION. 1.1 Purchase and...Stock Exchange Agreement • April 4th, 2000 • Sangui Biotech International Inc • Non-operating establishments • California
Remuneration Agreement betweenRemuneration Agreement • October 5th, 2012 • Sangui Biotech International Inc • Pharmaceutical preparations
EMPLOYMENT AGREEMENT (Ulrike Dickmann)Employment Agreement • September 18th, 2015 • Sangui Biotech International Inc • Pharmaceutical preparations • California
This Employment Agreement (the "Agreement") is entered into and effective as of September 17, 2015 (the Effective Date”) by and between National Graphite Corp., a Nevada corporation (the “Company” or “NGRC"), and Ulrike Dickmann (“Executive”).
SanguiBioTech GmbH and Fanales GmbH cooperate in marketing and sales of PURE MO2ISTURE cosmeticsSangui Biotech International Inc • November 19th, 2008 • Pharmaceutical preparations
Witten, Germany, October 21, 2008 - SanguiBioTech GmbH and Fanales GmbH, Recklinghausen, Germany, intend to cooperate in marketing and sales of PURE MO2ISTURE cosmetics. The agreement to this effect comprises an initial test phase of six months. Under the terms of the mutually non-exclusive agreement, Fanales will sell Sangui's PURE MO2ISTURE cosmetics in a specialized shop in Dusseldorf and strive to establish additional distribution channels. Sangui will deliver the required quantities and provide information and marketing support.
Loan Agreement between Feedback AG Neuer Wall 54 20354 Hamburg Represented by Dr. Christoph Ludz and Thomas Striepe, Members of the Board (subsequently „FeedBack”) and Sangui BioTech International, Inc. Alfred-Herrhausen-Str.44 58455 Witten...Loan Agreement • June 14th, 2007 • Sangui Biotech International Inc • Pharmaceutical preparations
Arabian companies will start selling Sangui products in the course of next few monthsSangui Biotech International Inc • June 14th, 2007 • Pharmaceutical preparations
Witten, Dubai, May 23, 2007 – Comprehensive marketing and distribution agreements to this effect have been signed between Sheikh Al Mudhareb, TYCOON Consulting (UK) Ltd. and SanguiBioTech GmbH after a series of presentations and in depth negotiations in Sharjah and Dubai. Products covered by the terms of the contracts include the whole range of Sangui’s present and future cosmetics products as well as the range of medical products if and when certified for distribution in these markets. This refers in particular to Sangui’s ChitoSkin wound pads based on bovine gelatine and the HemoSpray based on camel blood.
Loan Agreement Between Feedback AG Hamburg Represented by Dr. Christoph Ludz and Thomas Striepe, Members of the Board (subsequently „FeedBack”) And Sangui BioTech International, Inc. Alfred-Herrhausen-Str.44 58455 Witten Represented by Prof. Wolfgang...Loan Agreement • June 14th, 2007 • Sangui Biotech International Inc • Pharmaceutical preparations
Assignment of patents of Professor Dr. Wolfgang Barnikol to Sangui Biotech, AG & GlukoMeditech, AG Date: 29 October 1996 (sic - actual date was 7 July 1997) This agreement is made and executed between Professor Wolfgang Barnikol and Sangui Biotech, AG...Sangui Biotech International Inc • November 20th, 2000 • Non-operating establishments
COOPERATION AND MARKETING AGREEMENT between Karl Beese (GmbH & Co.), Barsbüttel (henceforth “Beese”) and Sangui GmbH, Witten (henceforth “Sangui”) PreambleCooperation and Marketing Agreement • June 14th, 2007 • Sangui Biotech International Inc • Pharmaceutical preparations
Sangui has developed a chitosan based wound pad (Chitoskin). Beese has already established processes to sterilize and package such wound pads on behalf of Sangui. Beese is interested in marketing the Chitoskin product. The parties agree that these wound pads have unique properties which significantly differentiate them from other existing wound pads. Related patents have been applied for on an international level.
SERVICE CONTRACT Between SanguiBioTech AG Forschungs- und Entwicklungszentrum (FEZ) Alfred-Herrhausen-Str. 44 D-58455 Witten an der Ruhr represented by the Supervisory Board, the latter represented by its President, Axel J. Kutscher, Frankensteiner...Service Contract • October 13th, 2000 • Sangui Biotech International Inc • Non-operating establishments
Sangui and SastoMed Complement Licensing Agreement in View of Increasing Sales Success Witten, Germany, August 27, 2012Sangui Biotech International Inc • September 5th, 2012 • Pharmaceutical preparations
Sangui BioTech GmbH and SastoMed GmbH cordially adjusted the existing sales strategy as the introduction of Granulox to professional circles proves to be increasingly successful. In consideration of corresponding contributions the existing licensing contract was partially complemented resulting in the following conditions:
Exhibit 99.1Sangui Biotech International Inc • November 17th, 2004 • Pharmaceutical preparations
This news release includes statements, other than historical fact, that may be deemed forward-looking. These statements may be accompanied by words such as "believe," "estimate," "project," "expect," "anticipate," or "predict" that conveys the uncertainty of future events or outcomes. These statements are based on assumptions that the Company believes are reasonable; however, many factors could cause the Company's actual results in the future to differ materially from the forward-looking statements made herein and in any other documents or oral presentations made by, or on behalf of, the Company. Important factors which could cause actual results to differ materially from those in forward-looking statements include, among others, the ability to obtain additional financing, which is not assured; rapid technological developments and changes; problems in developments of the Company's products; price and product competition by competitors; general economic conditions; and factors discussed
STANDARD OFFICE LEASE BROOKHOLLOW OFFICE PARK By and Between John Hancock Mutual Life Insurance Company, as Lessor and Sangui Bio Tech, Inc., as Lessee Dated: September 4,1996Office Lease Brookhollow • November 20th, 2000 • Sangui Biotech International Inc • Non-operating establishments • California
Loan Agreement between FID Esprit AG Rosengartenstrasse 4 CH-8608 Bubikon Represented by Axel Kutscher (subsequently „FID Esprit”) and Sangui BioTech International, Inc. Alfred-Herrhausen-Str.44 58455 Witten Represented by Prof. Wolfgang Barnikol...Loan Agreement • June 14th, 2007 • Sangui Biotech International Inc • Pharmaceutical preparations
HEADS OF AGREEMENTHeads of Agreement • June 14th, 2007 • Sangui Biotech International Inc • Pharmaceutical preparations • Hamburg
Sangui has invented and developed certain haemoglobin based products and know-how for blood related pharmaceuticals/drug products and medical products such as an artificial oxygen carrier (Artificial Blood Additive), in the following “Additive” and wound protection devices such as Hemo-Spray, wound cleaner liquid/gel and Chitoskin wound pads, in the following “Hemo, WCL/G and Chito”. Sangui holds all related intellectual property rights including – but not limited to – various patents and patents rights pending for registration as well as the production know-how. The Additive as well as the Hemo, WCL/G and Chito shall obtain proper registration either as pharmaceuticals/drug products or medical products in order to be marketed and applied to patients in the whole world.
